Drug Trial Radar · NCT05319730
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
May 16, 2023
Primary completion
Jun 11, 2027
Study completion Apr 10, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
PaclitaxelDrug
80-100 mg/m\^2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
IrinotecanDrug
180 mg/m\^2 IV infusion, administered on day 1 of every 14-day cycle.
PembrolizumabBiological
200 mg IV infusion, administered every Q3W up to 35 infusions.
MK-4830Biological
800 mg IV infusion, administered Q3W up to 35 infusions.
LenvatinibDrug
20 mg oral administration every day.
Sacituzumab tirumotecanBiological
4 mg/kg or 5 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
AntihistamineDrug
Administered per product label.
H2 Receptor AntagonistDrug
Administered per product label.
Acetaminophen (or equivalent)Drug
Administered per product label.
Dexamethasone (or equivalent)Drug
Administered per product label.
Steroid Mouthwash (dexamethasone or equivalent)Drug
Administered per product label.
Supportive care measuresDrug
Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or ointment may be given as a supportive care for Ocular Surface Toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
- Number of Participants Who Experienced an Adverse Event (AE) During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
- Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
- Objective Response Rate (ORR)Time frame: Up to approximately 48 months
Locations
58 sites in 14 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)
Tucson, Arizona · Recruiting
UCLA Hematology/Oncology - Santa Monica ( Site 4905)
Los Angeles, California · Recruiting
Hematology-Oncology Associates of Central NY, P.C. ( Site 4925)
East Syracuse, New York · Recruiting
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907)
New York, New York · Completed
UPMC Hillman Cancer Center-UPMC ( Site 4904)
Pittsburgh, Pennsylvania · Recruiting
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300)
São Paulo, Brazil · Recruiting
Liga Norte Riograndense Contra o Câncer ( Site 4303)
Natal, Rio Grande do Norte, Brazil · Recruiting
Hospital Nossa Senhora da Conceição ( Site 4301)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
FALP-UIDO ( Site 4400)
Santiago, Region M. de Santiago, Chile · Recruiting
Centro de Oncología de Precisión-Oncology ( Site 4404)
Santiago, Region M. de Santiago, Chile · Recruiting
Clínica las Condes ( Site 4403)
Santiago, Region M. de Santiago, Chile · Completed
Clínica UC San Carlos de Apoquindo ( Site 4405)
Santiago, Region M. de Santiago, Chile · Recruiting
Anhui Provincial Hospital ( Site 3501)
Hefei, Anhui, China · Recruiting
Beijing Cancer hospital-Digestive Oncology ( Site 3500)
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Xiamen University ( Site 3516)
Xiamen, Fujian, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 3510)
Xinxiang, Henan, China · Recruiting
Henan Cancer Hospital ( Site 3518)
Zhengzhou, Henan, China · Recruiting
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 3506)
Huai'an, Jiangsu, China · Recruiting
Shanghai Chest Hospital-Esophageal surgery department ( Site 3513)
Shanghai, Shanghai Municipality, China · Recruiting
Zhejiang Cancer Hospital-Thoracic oncology ( Site 3511)
Hangzhou, Zhejiang, China · Recruiting
Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 4804)
Berlin, Germany · Completed
HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 4807)
Erdgeschoss, Free and Hanseatic City of Hamburg, Germany · Recruiting
Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 4801)
Frankfurt am Main, Hesse, Germany · Completed
Universitaetsklinikum Duesseldorf ( Site 4802)
Düsseldorf, North Rhine-Westphalia, Germany · Completed
Ospedale San Raffaele-Oncologia Medica ( Site 3202)
Milan, Italy · Recruiting
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( Site 3201)
Milan, Italy · Completed
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 3207)
Meldola, Emilia-Romagna, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3200)
Milan, Lombardy, Italy · Recruiting
Azienda Ospedaliero Universitaria Pisana ( Site 3206)
Pisa, Tuscany, Italy · Recruiting
Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 3203)
Padova, Veneto, Italy · Recruiting
Aichi Cancer Center ( Site 3702)
Nagoya, Aichi-ken, Japan · Recruiting
National Cancer Center Hospital East ( Site 3701)
Kashiwa, Chiba, Japan · Recruiting
Saitama Prefectural Cancer Center ( Site 3703)
Kitaadachi-gun, Saitama, Japan · Recruiting
Shizuoka Cancer Center ( Site 3704)
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan · Recruiting
National Cancer Center Hospital ( Site 3700)
Chuo-ku, Tokyo, Japan · Recruiting
Oslo universitetssykehus, Radiumhospitalet ( Site 4501)
Oslo, Norway · Recruiting
National University Hospital ( Site 3800)
Singapore, South West, Singapore · Recruiting
Asan Medical Center-Department of Oncology ( Site 3901)
Seoul, South Korea · Recruiting
Samsung Medical Center-Division of Hematology/Oncology ( Site 3900)
Seoul, South Korea · Recruiting
Hôpitaux Universitaires de Genève (HUG) ( Site 4702)
Geneva, Canton of Geneva, Switzerland · Recruiting
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.